CYP3A4*1B and NAT2*14 alleles in a native African population

Clinical Chemistry and Laboratory Medicine

Volumn 41, Issue 4, 2003, Pages 606-609

  Cavaco, Isa ^a,c   Reis, Rita ^a   Gil, J Pedro ^b,c   Ribeiro, Vera ^a,c  

^a UNIVERSIDADE DO ALGARVE   (Portugal)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF ALGARVE   (Portugal)

Author keywords

Africans; CYP3A4; N acytylation; NAT2; Polymorphism

Indexed keywords

ACYLTRANSFERASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIARRHYTHMIC AGENT; ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; ISONIAZID; MIDAZOLAM; RIFAMPICIN; TUBERCULOSTATIC AGENT; XENOBIOTIC AGENT; ARYLAMINE ACETYLTRANSFERASE; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; DNA; NAT2 PROTEIN, HUMAN; PRIMER DNA;

ACETYLATOR PHENOTYPE; AFRICA; ALLELE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; ENZYME METABOLISM; FEMALE; GENE FREQUENCY; GENETIC CODE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; POPULATION GENETICS; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; TUBERCULOSIS; UNITED STATES; BLOOD; COMPARATIVE STUDY; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; NEGRO; POLYMERASE CHAIN REACTION;

HUMAN IMMUNODEFICIENCY VIRUS;

AFRICAN CONTINENTAL ANCESTRY GROUP; ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; CYTOCHROME P-450 ENZYME SYSTEM; DNA; DNA PRIMERS; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 0037721320     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2003.091     Document Type: Article

References (31)

1. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Karolinska Institutet, Sweden (http://www.imm.ki.se/CYPalleles)
2. Rebbeck TR, Jaffe JM, Walker AH, Wain AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90:1225-9.
3. Walker AH, Jaffe JM, Gunasegaram S, Cummings SA, Huang CS, Chern HD, et al. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Hum Mutat 1998; 12:289.
4. Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung NV, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 1998; 95:13176-81.
5. Arylamine N-Acetyltransferase (NAT) Nomenclature Homepage. Univ. of Louisville School of Medicine. USA (http://www.louisville.edu/medschool/pharmacology/NAT.htm)
6. Fretland A, Leff M, Doll M, Hein D. Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics 2001; 11:207-15.
7. Walsh PS, Metzger DA, Higuchi R. Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. Biotechniques 1991; 10:506-13.
8. Gardner MJ, Altman DG, editors. Statistics with confidence. London: British Medical Journal, 1989.
9. Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, Mayer P, et al. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther 1999; 66:288-94.
10. Lamba JK, Lin YS, Thummel KE, Daly A, Watkins PB, Strom S, et al. Common allelic variants of Cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002; 12:121-32.
11. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54:1271-94.
12. Kittles RA, Chen W, Panguluri RK, Ahaghotu C, Jackson A, Adebamowo CA, et al. CYP3A4-V and prostate cancer in African Americans : causal or confounding association because of population stratification? Hum Genet 2002; 110:553-60.
13. Zeigler-Johnson CM, Walker AH, Mancke B, Spangler E, Jalloh N, McBride S, et al. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered 2002; 54:13-21.
14. Tayeb MT, Clark C, Ameyaw M, Haites NE, Evans DA, Tariq M, et al. CYP3A4 promoter variants in Saudi, Ghanaian and Scottish Caucasian populations. Pharmacogenetics 2000; 10:753-6.
15. Bell D, Taylor J, Butler M, Stephens E, Wiest J, Brubaker L, et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) revels a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993; 14:1689-92.
16. Delomenie C, Sica L, Grant D, Krishnamoorthy R, Dupret J. Genotyping of the polymorphic N-acetyltransferase (NAT2) gene locus in two native African populations. Pharmacogenetics 1996; 6:177-85.
17. Loktionov A, Moore W, Spencer SP, Vorster H, Nell T, O'Neill IK, et al. Differences in N-acetylation genotypes between Caucasians and Black South Africans: implications for cancer prevention. Cancer Detect Prev 2002; 26:15-22.
18. 191A mutation among Sudanese and Somalis. Pharmacogenetics 1997; 7:397-9.
19. Wood AJJ, Zhou HH Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991; 20:350-73.
20. Merril RM, Brawley OW. Prostate cancer incidence and mortality rates among white and black men. Epidemiology 1997; 8:126-31.
21. Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun 1999; 259:201-05.
22. Amirimani B, Walker AH, Weber BL, Rebbeck TR. Response to Ando et al. Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1999; 91:1588-90.
23. Ando Y, Tateishi T, Sekido Y, Yamamoto T, Satoh T, Hasegawa Y, et al. Re:modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1999; 91:1587-8.
24. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B 5′-promoter region polymorphism. Clin Pharmacol Ther 2000; 68:82-91.
25. Tayeb MT, Clark C, Sharp L, Haites NE, Rooney PH, Murry GI, et al. CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncol Rep 2002; 9:653-5.
26. Wojnowski L, Hustert E, Klein K, Goldammer M, Haberl M, Kirchheiner J, et al. Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 2002; 94:630-1.
27. Olderogge D. Migrations et différenciations ethniques et linguistiques. In: Ki-Zerbo J, editor. Histoire generale de I'Afrique. I. Méthodologie et préhistoire Africaine. Paris, France: UNESCO, 1989:301-20.
28. Antunes A, Nina J, David S. Serological screening for tuberculosis in the community: an evaluation of the Mycodot procedure in an African population with high HIV-2 prevalence (Republic of Guinea-Bissau). Res Microbiol 2002; 153:301-5.
29. Levy GN, Weber WW. Acetyltransferases. In: Ioannides C, editor. Handbook of enzyme systems that metabolise drugs and other xenobiotics. Surrey, England: J Wiley, & Sons, Ltd, 200:441-57.
30. Desta Z, Soukhova N, Flockhart D. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother 2001; 45:382-92.
31. CDC & prevention - Panel on clinical Practices for Treatment of HIV. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. MMWR Recomm Rep 2002; 51(RR7):47-8.